Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model.

Ghosh SK, Uchida M, Yoo B, Ross AW, Gendler SJ, Gong J, Moore A, Medarova Z.

Int J Cancer. 2013 Apr 15;132(8):1860-7. doi: 10.1002/ijc.27872. Epub 2012 Oct 25.

PMID:
23015160
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging.

Medarova Z, Rashkovetsky L, Pantazopoulos P, Moore A.

Cancer Res. 2009 Feb 1;69(3):1182-9. doi: 10.1158/0008-5472.CAN-08-2001. Epub 2009 Jan 13.

PMID:
19141648
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.

Moase EH, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, Ding L, Krantz M, Allen TM.

Biochim Biophys Acta. 2001 Feb 9;1510(1-2):43-55.

PMID:
11342146
[PubMed - indexed for MEDLINE]
Free Article
4.

Cross-linked iron oxide–C-AHA-AREPPTRTFAYWGK(FITC).

The MICAD Research Team.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2006 Jul 26 [updated 2006 Aug 14].

PMID:
20641786
[PubMed]
Books & Documents
5.

Image-guided breast tumor therapy using a small interfering RNA nanodrug.

Kumar M, Yigit M, Dai G, Moore A, Medarova Z.

Cancer Res. 2010 Oct 1;70(19):7553-61. doi: 10.1158/0008-5472.CAN-10-2070. Epub 2010 Aug 11.

PMID:
20702603
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Engineered breast tumor targeting peptide ligand modified liposomal doxorubicin and the effect of peptide density on anticancer activity.

Shahin M, Soudy R, Aliabadi HM, Kneteman N, Kaur K, Lavasanifar A.

Biomaterials. 2013 May;34(16):4089-97. doi: 10.1016/j.biomaterials.2013.02.019. Epub 2013 Mar 5.

PMID:
23465829
[PubMed - indexed for MEDLINE]
7.

STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas.

Chan SR, Vermi W, Luo J, Lucini L, Rickert C, Fowler AM, Lonardi S, Arthur C, Young LJ, Levy DE, Welch MJ, Cardiff RD, Schreiber RD.

Breast Cancer Res. 2012 Jan 20;14(1):R16.

PMID:
22264274
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP-2 gene transfer.

Lee YK, So IS, Lee SC, Lee JH, Lee CW, Kim WM, Park MK, Lee ST, Park DY, Shin DY, Park CU, Kim YS.

J Gene Med. 2005 Feb;7(2):145-57.

PMID:
15546163
[PubMed - indexed for MEDLINE]
9.

In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe.

Moore A, Medarova Z, Potthast A, Dai G.

Cancer Res. 2004 Mar 1;64(5):1821-7.

PMID:
14996745
[PubMed - indexed for MEDLINE]
Free Article
10.

Blockade of MUC1 expression by glycerol guaiacolate inhibits proliferation of human breast cancer cells.

Smith JS, Colon J, Madero-Visbal R, Isley B, Konduri SD, Baker CH.

Anticancer Agents Med Chem. 2010 Oct 1;10(8):644-6650.

PMID:
21184665
[PubMed - indexed for MEDLINE]
11.

Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.

Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL, Schwertfeger KL, Lange CA.

Breast Cancer Res. 2011 Sep 17;13(5):R89. doi: 10.1186/bcr2946.

PMID:
21923922
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1.

Carr-Brendel V, Markovic D, Ferrer K, Smith M, Taylor-Papadimitriou J, Cohen EP.

Cancer Res. 2000 May 1;60(9):2435-43.

PMID:
10811121
[PubMed - indexed for MEDLINE]
Free Article
13.

Metastasis is an early event in mouse mammary carcinomas and is associated with cells bearing stem cell markers.

Weng D, Penzner JH, Song B, Koido S, Calderwood SK, Gong J.

Breast Cancer Res. 2012 Jan 25;14(1):R18.

PMID:
22277639
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.

Bajo AM, Schally AV, Halmos G, Nagy A.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3742-8.

PMID:
14506166
[PubMed - indexed for MEDLINE]
Free Article
15.

Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.

Mukherjee P, Madsen CS, Ginardi AR, Tinder TL, Jacobs F, Parker J, Agrawal B, Longenecker BM, Gendler SJ.

J Immunother. 2003 Jan-Feb;26(1):47-62.

PMID:
12514429
[PubMed - indexed for MEDLINE]
16.

Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.

Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS.

Breast Cancer Res. 2008;10(2):R22. doi: 10.1186/bcr1874. Epub 2008 Mar 7.

PMID:
18328103
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.

Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong WL, Hollingshead P, Schwall R, Koeppen H, Erickson S.

Clin Cancer Res. 2004 Apr 1;10(7):2499-511.

PMID:
15073130
[PubMed - indexed for MEDLINE]
Free Article
18.

Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model.

Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB.

Breast Cancer Res. 2004;6(4):R275-83. Epub 2004 Apr 7.

PMID:
15217493
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.

Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler SJ, Kufe D, Gong J.

Immunology. 2003 Jun;109(2):300-7.

PMID:
12757626
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.

Paliwal SR, Paliwal R, Pal HC, Saxena AK, Sharma PR, Gupta PN, Agrawal GP, Vyas SP.

Mol Pharm. 2012 Jan 1;9(1):176-86. doi: 10.1021/mp200439z. Epub 2011 Nov 28.

PMID:
22091702
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk